Literature DB >> 7105052

Vomiting induced by cyclophosphamide and phosphoramide mustard in cats.

J H Fetting, L E McCarthy, H L Borison, M Colvin.   

Abstract

Cyclophosphamide and phosphoramide mustard produce significant vomiting. Cyclophosphamide is metabolized to phosphoramide mustard, which may ultimately contribute to vomiting after cyclophosphamide administration. The role of the chemoreceptor trigger zone (CTZ) in vomiting caused by these agents is unknown. We studied the emetic syndromes produced by iv and intracerebroventricular cyclophosphamide and phosphoramide mustard in unanesthetized normal and CTZ-ablated cats. Iv cyclophosphamide produced vomiting unpredictably, with a mean latency of 54 +/- 9 mins (mean +/- SE) in cats that vomited. A dose-response relationship was found for phosphoramide mustard-induced emesis. A dose of 200 mg/kg was consistently effective, with a mean latency of 127 +/- 6 mins. Neither agent produced predictable emesis by the intracerebroventricular route of administration. One of four CTZ-ablated cats vomited after 300 mg/kg of cyclophosphamide. Since cyclophosphamide was an unpredictable emetic stimulus, it was not possible to further evaluate the effect of CTZ ablation on cyclophosphamide-induced vomiting. However, CTZ-ablated cats given 200 mg/kg of phosphoramide mustard vomited significantly less frequently (P = 0.05 by chi-square test) and with a longer latency than nonablated animals. A temporary, severe neurotoxic reaction was observed in cats receiving greater than or equal to 3400 mg/kg of cyclophosphamide, which may have had an inhibitory effect on emesis. Phosphoramide mustard was found to be a potent emetic stimulus in cats and may contribute to the emetic response following cyclophosphamide administration. Analysis of latency data suggests that in the cat other cyclophosphamide metabolites may also contribute to the emetic syndrome.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105052

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  5 in total

Review 1.  Neuropharmacology of emesis in relation to clinical response.

Authors:  B Costall; R J Naylor
Journal:  Br J Cancer Suppl       Date:  1992-12

2.  Influence of glutathione S transferase A1 gene polymorphism (-69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis.

Authors:  Doaa H S Attia; Mervat Eissa; Lamees A Samy; Rasha A Khattab
Journal:  Clin Rheumatol       Date:  2020-07-13       Impact factor: 2.980

3.  Neuropharmacology of chemotherapy-induced emesis.

Authors:  H L Borison; L E McCarthy
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

Review 4.  Antiemetics in cancer chemotherapy: historical perspective and current state of the art.

Authors:  M Tonato; F Roila; A Del Favero; E Ballatori
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

Review 5.  Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases.

Authors:  Paul L R Andrews; Charles C Horn
Journal:  Auton Neurosci       Date:  2006-03-23       Impact factor: 3.145

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.